AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01232621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician Introduction of research personnel
Description: Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.
Study NCT04679051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep duration
Description: Participants will be asked to alter time in bed to achieve specified sleep durations.
Study NCT04288817 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tuberculin purified protein derivative
Description: Intralesional injection of tuberculin PPD in treatment of multiple common warts
Study NCT00864838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 250 mg 1 hour before intravitreal injection
Study NCT00864838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartarate
Description: 1 drop 1 hour before intravitreal injection
Study NCT00864838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior chamber paracentesis
Description: Immediately after bevacizumab injection
Study NCT01339988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan/Cyclophosphamide
Description: Conditioning regimen:~Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days.
Study NCT03706157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
Description: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
Study NCT03706157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
Description: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
Study NCT04399187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium hypochlorite gel application
Description: Patients treated by scaling and root planing and Sodium hypochlorite gel application, meanwhile in patients of control group scaling and root planing alone was performed.
Study NCT04399187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite gel application
Description: Patients treated by scaling and root planing and Sodium hypochlorite gel application, meanwhile in patients of control group scaling and root planing alone was performed.
Study NCT04448236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction resistance exercise
Description: Application the Blood flow restriction device over the proximal thigh to have 80% of the limb occlusion pressure to accumulate the metabolite generated during knee extension
Study NCT01402167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Description: Patients will be treated via a balloon kyphoplasty surgical procedure
Study NCT01402167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Patients will be treated via a transcutaneous vertebroplasty procedure.
Study NCT04545294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta tACS
Description: See detail in arm/group descriptions regarding the intervention.
Study NCT04545294 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theta tACS
Description: See detail in arm/group descriptions regarding the intervention.
Study NCT01666054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSV
Description: Pressure Support Ventilation will be used until patient is extubated
Study NCT01666054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAV
Description: Proportional Assist Ventilation will be used until patient is extubated.
Study NCT00744237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: * Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~* Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~* Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~* Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration
Study NCT00744237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol ER
Description: * Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~* Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~* Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~* Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration
Study NCT00744237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: * HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~* HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration
Study NCT02240589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.
Study NCT02240589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.
Study NCT00030368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00030368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00030368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04020003 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levosimendan
Description: General treatment group: control the infection, remove or control the original disease, mechanical ventilation, small tidal volume, high PEEP mechanical ventilation strategy, strictly control the capacity, strengthen the airway management, timely nutrition support and intensive rehabilitation treatment. Levosimendan group: on the basis of routine group treatment, 12.5 mg of levosimendan 5% GS 50ml was given on the same day, and the micro-pump was continuously pumped for 24 hours. The initial dose was 0.5 ml/ h, and if the blood pressure was not significantly decreased, the blood pressure was gradually increased to 2.4 ml/ h at the maximum dose, until the pump was over. The above treatment is repeated every 7 days until the offline success or the patient leaves the ICU.
Study NCT03481790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: (Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.
Study NCT03481790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferrous sulphate + folic acid (vitamin B9)
Description: (Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.
Study NCT03004664 — intervention group
Intervention type: BEHAVIORAL
Intervention: Support Empowerment Model
Description: The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions.
Study NCT03004664 — intervention group
Intervention type: BEHAVIORAL
Intervention: The Chronic Care Model
Description: the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design
Study NCT04161417 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling
Description: Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study
Study NCT02492646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline group
Description: After anesthetic induction, patients will be intubated with endotracheal tube which was immersed in normal saline before intubation.
Study NCT02492646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry group
Description: After anesthetic induction, patients will be intubated with endotracheal tube which was not immersed in normal saline.
Study NCT01649596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warming Gown
Description: Forced air warming Gown and portable warming unit that follows patient from pre-operative through surgery and into post-operative recovery.
Study NCT01649596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care warming
Description: The intervention is standard of care, placing warm blankets on the patient at time of pre operative preparation through the procedure and into recovery.
Study NCT00164853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic balloon dilatation
Description: Refer to description under arms
Study NCT00164853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sphincterotomy
Description: Refer to under arms
Study NCT00720408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf-XL
Description: oral
Study NCT00720408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral
Study NCT00720408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: oral
Study NCT00720408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: oral
Study NCT03685032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The 4 mg of dexamethasone in 1 ml intravenous was administrated after patient received general anesthesia
Study NCT03685032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: The 4 mg of ondansetron in 2 ml intravenous was administrated at the end of the operation.
Study NCT03685032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: The 0.9% sodium chloride in 1 ml intravenous was administrated after patient received general anesthesia. At the end of operation, the 0.9% sodium chloride in 2 ml intravenous was administrated.
Study NCT02091869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paper Asthma Action Plan
Description: Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.
Study NCT02091869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Phone
Description: Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
Study NCT02279147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neostigmine methylsulfate，raceanisodamine hydrochloride
Description: The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
Study NCT02406885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
Study NCT04396223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Injection
Description: Avelumab administration at 800mg a 1 hour IV infusion once every 14 days during 4 months ½ (median)
Study NCT04396223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate 1 GM Injection
Description: methotrexate administration at 1mg/kg/day during 4 months ½ (median)
Study NCT01414413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home assessment and initiation of ART
Description: Home-based ART eligibility assessment (WHO staging, CD4 count measurement and educational treatment preparation) and initiation.
Study NCT01414413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinic-based ART assessment and initiation
Description: Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor.
Study NCT04238403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (MATCH Protocol)
Description: BPT. Behavioral Parent Training (BPT) is a well-established psychosocial intervention for the treatment for ADHD and related behavioral difficulties (e.g., oppositional problems). BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods (e.g., praise, effective communication, reward systems, time-out from positive reinforcement) to facilitate positive behaviors in their child (e.g., compliance) and reduce challenging behaviors (e.g., opposition). BPT comes in several manualized, commercially available manuals. The version of BPT that we will be utilizing is from the MATCH protocol (Chorpita and Weisz, 2009), which consists of 10 components, delivered with individual families, typically over the course of 10-16 weekly individual meetings (total meetings depends upon parent availability and acquisition of BPT skills).
Study NCT02393326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial pulpotomy with biodentine
Description: After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol
Study NCT02393326 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Formocresol pulpotomy
Description: Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
Study NCT03957811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body Vibration exercise
Description: Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.
Study NCT02839564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic adhesiolysis
Description: After diagnostic laparoscopy to confirm adhesions and exclude other pathology laparoscopic adhesiolysis was performed
Study NCT02839564 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Diagnostic laparoscopy
Description: After diagnostic laparoscopy to confirm adhesions and exclude other pathology treatment was stopped.
Study NCT03456999 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MAU868
Description: MAU868 infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses.
Study NCT03456999 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution containing no active excipients, infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses
Study NCT00971061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed valve implant
Description: 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
Study NCT00971061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molteno single-plate implant (MSPI)
Description: 134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
Study NCT02744482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: risedrante tablet (75 mg)
Study NCT02744482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: risedrante placebo tablet (75 mg)
Study NCT02079142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Strategy: Train-the-trainer
Description: Trainers in the high intensity condition will attend two separate workshops at Washington University in St. Louis designed to teach participants to conduct IPT and then to train IPT. Following participation in the first, two-day workshop, each trainer will return to their site and be encouraged to treat at least two cases with eating disorders or depression, audio recording each session.~Trainers will then return to Washington University to be trained in how to train their other staff members in IPT.
Study NCT02079142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Strategy: Expert Consultation
Description: Investigators will provide a two-day workshop on IPT at each site randomized to this condition to train therapists to use IPT for the treatment of Eating Disorders and depression.
Study NCT00002756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Study NCT00002756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00002756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study NCT00002756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00002756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00002756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study NCT00002756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00002756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00002756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Study NCT00002756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT02339155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVA
Description: Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
Study NCT02044341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR01
Description: drops administered an needed for pain
Study NCT02044341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycerin ear drops
Description: placebo drops administered for ear pain
Study NCT03328910 — intervention group
Intervention type: DEVICE
Intervention: SPI monitor (GE Healthcare, Helsinki, Finland)
Description: The SPI is derived from pulse rate and pulse wave amplitude measured with photoplethysmography, obtained from the CARESCAPE B650 monitor (GE Healthcare, Finland) with a scale from 1 to 100.
Study NCT02183077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam gel
Study NCT02183077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam tablet
Study NCT02339155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Raxibacumab
Description: Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
Study NCT02339155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
Study NCT01393613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Higher dose tablet, once daily, for six weeks,
Study NCT01393613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Middle dose tablet, once daily, for six weeks
Study NCT01393613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Lower dose tablet, once daily, for six weeks
Study NCT01393613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, for six weeks
Study NCT03321461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMTP1
Description: Fluorescent sites will be removed
Study NCT03321461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICG
Description: Fluorescent sites will be removed
Study NCT04498416 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative and qualitative assessments of mental health
Description: Emergency semi-directed interview; Diagnosis Infant and Preschool Assessment (DIPA); Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS); Conners Scale - short version;Weiss functional impairment rating scale - parent (WFIRS); Parenting stress index-short form (PSI-SF); Anxiety Scale
Study NCT03919500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO
Description: Infants in EPO group are administered 500IU/kg intravenously within 72 hours after birth every other day for 2 weeks.
Study NCT03919500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Infants in control group are administered normal saline with the same volume and period as EPO.
Study NCT02631746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies